Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

Shots: Eli Lilly to acquire Scorpion, plus its leading asset STX-478, for ~2.5B in cash, incl. upfront, regulatory & sales milestones through a definitive agreement As per the terms, Scorpion will form an independent company owned by its current shareholders with Lilly’s minority stake to hold its employees & non-PI3Kα pipeline assets STX-478 (oral,…

ByDipanshu DixitJanuary 14, 2025

NEWS

Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio

Shots: J&J entered into a definitive agreement to acquire Intra-Cellular Therapies, incl. its drugs Caplyta & ITI-1284, for a total equity value of ~14.6B (cash + debt), with shareholders receiving $132/share in cash, making the latter private In Dec 2024, the latter filed an sNDA to the US FDA for Caplyta as adj. therapy…

ByDipanshu DixitJanuary 14, 2025

NEWS

GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio

Shots: GSK to acquire IDRx incl. its lead candidate IDRX-42, for $1B upfront & ~$150M in regulatory milestones (total ~$1.15B). It will also pay success-based milestones & tiered royalties to Merck KGaA for IDRX-42 IDRX-42 (TKI, small molecule) targets key KIT mutations, responsible for proliferation & survival of tumor cells, & is under P-I/Ib…

BySenior EditorJanuary 13, 2025

NEWS

Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio

Shots: Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked…

BySenior EditorJanuary 10, 2025

NEWS

Transcarent to Acquire Accolade for ~$621M

Shots: Transcarent to acquire Accolade with a total equity value of ~$621M, with shareholders receiving $7.03/share in cash, making Accolade private. Closing expected in Q2’25 The acquisition will yield a unified platform with Transcarent’s WayFinding (generative AI), pharmacy benefits & overall care experiences (incl. weight health, cancer & surgery care) & Accolade’s data of…

BySenior EditorJanuary 9, 2025

NEWS

Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics

Shots: Vividion (Bayer’s subsidiary) has acquired Tavros to strengthen its genomic capabilities via Tavros’ platform. The financial terms are undisclosed The acquisition strengthens Vividion’s functional genomics expertise by adding proprietary genomic screening approaches to discover new targets & translate the known ones. Combining resources from both the companies will enable drug discovery in oncology…

BySenior EditorJanuary 9, 2025

NEWS

ScreenPoint Medical Reports the Acquisition of Biomediq, Bolstering its Breast Cancer Risk Evaluation Capabilities

Shots: ScreenPoint has acquired Biomediq, enhancing its breast cancer risk evaluation abilities by adding Breast AI platform, Transpara, that uses Mammographic Texture Risk biomarkers to analyze 2D & 3D mammograms & predict short & long-term risk ScreenPoint has launched Transpara 2.1, with advanced features like automated breast density evaluation (BIRADS & volumetric) & temporal…

BySenior EditorJanuary 9, 2025

NEWS

Boston Scientific to Acquire Bolt Medical, Strengthening its Cardiovascular Portfolio

Shots: Boston Scientific has agreed to acquire Bolt Medical, strengthening its cardiovascular portfolio with the addition of Bolt IVL system for coronary & peripheral disease. Deal is expected to close in H1’25 Boston, an investor with a 26% equity stake in Bolt Medical, is acquiring the rest 74% for $443M upfront & up to…

BySenior EditorJanuary 9, 2025

NEWS

Hologic Completes the Acquisition of Gynesonics for ~$350M

Shots: Hologic has completed the acquisition of Gynesonics, focused on developing minimally invasive women’s health solutions, for ~$350M The acquisition has strengthened Hologic's portfolio with the addition of Sonata System, a minimally invasive solution for heavy periods & fibroids The Sonata System is developed to capture intrauterine images for diagnosis and transcervical treatment…

BySenior EditorJanuary 7, 2025

NEWS

Stryker to Acquire Inari Medical for ~$4.9B

Shots: Stryker has signed a definitive agreement to initiate a tender offer for acquiring all the issued & outstanding shares of Inari Medical for $80 per share in cash, making it a total value of ~$4.9B Upon completion, Stryker will acquire remaining shares in a second-step merger at the same price. The deal is…

BySenior EditorJanuary 7, 2025

Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio

GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio

Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio

Transcarent to Acquire Accolade for ~$621M

Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics

ScreenPoint Medical Reports the Acquisition of Biomediq, Bolstering its Breast Cancer Risk Evaluation Capabilities

Boston Scientific to Acquire Bolt Medical, Strengthening its Cardiovascular Portfolio

Hologic Completes the Acquisition of Gynesonics for ~$350M

Stryker to Acquire Inari Medical for ~$4.9B

Contact US

FOLLOW US